Clinical trials: Nephropathy
End-Stage Renal Disease
Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients
The purpose of this study is to determine how levels of this newly-discovered hormone, called FGF-23, changes in the blood in response to a high calcium dialysis bath during a hemodialysis (HD) treatment, and how this relates to…
- Trial name
- NCT00477516
- Testing
- exposure to a high-calcium dialysate bath
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- James B. Wetmore, MD
Chronic Kidney Disease
Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease
N-acetylcysteine is used to reduce the risk of injury to the kidney after the administration of contrast dye. The mechanism and effectiveness of this intervention is not substantiated in the literature.
- Trial name
- NCT00506506
- Testing
- N-acetylcysteine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Acute Renal Failure, Chronic Kidney Failure
The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
To understand how AKI (Acute Kidney Injury) leads to chronic kidney disease so therapies can be found to alter the progression of events thereby significantly impacting the long-term outcomes of children who develop AKI.
- Conditions
- Acute Renal Failure, Chronic Kidney Failure, Endothelial Dysfunction, Hemolytic-uremic Syndrome (HUS)
- Trial name
- NCT00358306
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Secondary Hyperparathyroidism
A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
To examine efficacy and safety after 12-week administration of ASP7991 in secondary hyperparathyroidism patients undergoing hemodialysis
- Trial name
- NCT02133404
- Testing
- ASP7991, Cinacalcet
- Where
- 6 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Astellas Pharma Inc
Renal Failure, Left Ventricular Hypertrophy
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic…
- Trial name
- NCT00602004
- Testing
- losartan
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Melbourne Health
Coronary Artery Disease, Angina, Unstable
Contrast-associated Acute Kidney Injury in Patients With Different Types of Coronary Artery Disease
The goal of the study is to assess the prevalence of contrast-associated acute kidney injury in patients with stable coronary artery disease, ST-elevation myocardial infarction and unstable angina/NSTEMI, assess the risk factors…
- Conditions
- Coronary Artery Disease, Angina, Unstable, Angina, Stable, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT04163484
- Testing
- Iodinated contrast
- Where
- Russia
- Volunteers
- 156 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
End Stage Renal Disease
Choice Sets for Advance Directives
There is a large gap between the care seriously ill patients want and the care they receive. Advance directives (ADs) offer an opportunity for patients to express specific end-of-life preferences to avoid unwanted care.
- Trial name
- NCT02209038
- Testing
- Expanded AD Choice, Expanded Life-sustaining Therapy Choice
- Where
- 15 sites in United States
- Volunteers
- 321 people
- Sponsor
- University of Pennsylvania
Autoimmune Diseases
Complement C5 mAb in the Treatment of Anti-GBM Disease
Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.
- Trial name
- NCT06513338
- Testing
- Eculizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University First Hospital
Renal Cell Carcinoma
DC1s-CTL Cellular Therapy for Renal Cell Carcinoma
This trial is to evaluate the safety and effectiveness of autologous type-1 polarized dendritic cell vaccines (patients' autologous DC1s loaded with multiple antigens CTL epitope peptide complexes), after radical resection for…
- Trial name
- NCT02787915
- Testing
- DC1-CTL
- Volunteers
- 50 people
- Sponsor
- Xuzhou Medical University
Renal Cell Carcinoma
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been…
- Trial name
- NCT03427476
- Testing
- CTT1057
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cancer Targeted Technology
Chatbot-Based Training, Hemodialysis
DialysisBot: AI Chatbot for Hemodialysis Self-Management
End-stage kidney disease requiring hemodialysis is a chronic condition with substantial clinical, functional, and psychosocial burden.
- Conditions
- Chatbot-Based Training, Hemodialysis, Self-management
- Trial name
- NCT07830810
- Testing
- DialysisBot
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Rome Tor Vergata
Chronic Kidney Disease
A Risk Based Approach to Improving Chronic Kidney Disease Management
Aim 1: To assess whether quality of care for stage 3 chronic kidney disease can be substantially improved over 18 months by: Point of care electronic alerts to primary care physicians recommending risk-appropriate care, and…
- Trial name
- NCT01203813
- Testing
- Electronic Decision Support
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Brigham and Women's Hospital
IgA Nephropathy
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
This is a Phase II, open-label study designed to To evaluate the safety and efficacy of NM8074 in reducing proteinuria relative to baseline in IgAN patients after 99 days of treatment.
- Trial name
- NCT06454110
- Testing
- NM8074
- Volunteers
- 10 people
- Sponsor
- NovelMed Therapeutics
Proteinuria
The Effects of Weight Reduction in IgA Nephropathy
The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.
- Trial name
- WeightPro (NCT01773382)
- Testing
- weight reduction
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
End Stage Kidney Disease (ESRD)
Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)
The AMPLIFI-1 Study is a prospective, multicenter pivotal clinical trial designed to evaluate the safety and effectiveness of the Amplifi™ Vein Dilation System in patients requiring distal arteriovenous fistula (AVF) creation for…
- Trial name
- AMPLIFI-1 (NCT07211035)
- Testing
- The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation., Standard of Care (AVF creation)
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- Amplifi Vascular, Inc.
End-stage Renal Failure, Kidney Graft Rejection
Reference Group Trial for The ONE Study
To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen.
- Trial name
- NCT01656135
- Testing
- Blood drawing for immune monitoring and questionnaires
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- University of Regensburg
Systemic Lupus Erythematosus, Lupus
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
This is a Phase 1 study to evaluate the safety and efficacy of a single infusion of CB-010 in patients with refractory Systemic Lupus Erythematosus (SLE) with cohorts for lupus nephritis (LN) and extrarenal lupus (ERL).
- Conditions
- Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis
- Trial name
- GALLOP (NCT06752876)
- Testing
- CB-010
- Sponsor
- Caribou Biosciences, Inc.
Immunosuppression, Cancer
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due…
- Conditions
- Immunosuppression, Cancer, COVID-19, Other Complication of Kidney Transplant
- Trial name
- SOROCOV (NCT04834089)
- Testing
- AntiSARS-CoV-2 Serum
- Where
- 2 sites in Brazil
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Liver Cirrhosis, Acute Kidney Injury
RAI & HRS: Relationship Between Relative Adrenal Insufficiency and Failure of Treatment in Hepatorenal Syndrome
Hepatorenal syndrome is a life-threatening medical condition and a serious complication of advanced liver scarring (cirrhosis). It consists of a deterioration of the function of the kidneys caused by a severe alteration in the…
- Conditions
- Liver Cirrhosis, Acute Kidney Injury, Hepato-Renal Syndrome
- Trial name
- NCT04273750
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University Hospital Plymouth NHS Trust